Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL976393

N.N.N.O=C(O)C1=CC(C(c2ccc(O)c(C(=O)O)c2)c2ccc(O)c(C(=O)O)c2)C=CC1=O

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGO2 Q9UKV8 1/20 0.97
C9 P02748 3/20 0.44
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
HSD17B10 Q99714 4/20 0.43
TDP1 Q9NUW8 4/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 3/20 0.43
GRM1 Q13255 1/20 0.43
HSPD1 P10809 2/20 0.42
THRB P10828 2/20 0.42
ALOX15 P16050 2/20 0.42
BRCA1 P38398 2/20 0.42
RECQL P46063 2/20 0.42
HSPE1 P61604 2/20 0.42
HIF1A Q16665 2/20 0.42
IKBKB O14920 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5992669 0.99 AGO2 (1.00) AGO2C9KDM4EALDH1A1HPGD
SCHEMBL2833452 0.67 KDM4E (0.62) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1649282 0.67 ALDH1A1 (0.62) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9755165 0.67 KDM4E (0.67) AGO2C9KDM4EALDH1A1HPGD
SCHEMBL14381820 0.66 KDM4E (0.61) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10370338 0.64 KDM4E (0.62) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11233617 0.63 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL11217868 0.63 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL8428483 0.62 CA1 (0.58) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL658651 0.62 KDM4E (0.56) AGO2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240277742-A1 TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG CHI BIOTECH CO., LTD. (CN) 2024-08-22 US disclosed
WO-2023138011-A1 TRANSLATION INHIBITOR NOT OCCUPYING RIBOSOME RESOURCE AS ANTITUMOR DRUG 深圳承启生物科技有限公司 2023-07-27 WO disclosed
CN-114404400-A Translation inhibitor without occupying ribosome resource as antitumor drug 深圳承启生物科技有限公司 2022-04-29 CN disclosed
US-10589003-B2 Methods for coating surfaces with antimicrobial agents THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-03-17 US disclosed
US-20180303977-A1 METHODS FOR COATING SURFACES WITH ANTIMICROBIAL AGENTS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-10-25 US disclosed
CN-104560461-A Washing agent for mercury-polluted building wastes YANTAI SHUNLONG CHEMICAL TECHNOLOGY CO LTD 2015-04-29 CN disclosed
US-8053475-B2 Preparation of the formaurindikarboxyl acid base and its derivations and use Vyzkumny Ustav Zivocisne Vyroby, V.V.I. (CZ) 2011-11-08 US disclosed
US-8030353-B2 Preparation of the formaurindicarboxylic acid base and its derivations and use Vyzkumny Ustav Zivocisne Vyroby, V.V.I. (CZ) 2011-10-04 US disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
US-20110009490-A1 PREPARATION OF THE FORMAURINDIKARBOXYL ACID BASE AND ITS DERIVATIONS AND USE KLEIN PAVEL 2011-01-13 US disclosed
US-20090275661-A1 PREPARATION OF THE FORMAURINDICARBOXYLIC ACID BASE AND ITS DERIVATIONS AND USE VYKUMNY USTAV ZIVOCISNE VYROBY, V.V.I. (CZ) 2009-11-05 US disclosed
US-20080183152-A1 MEDICAL DEVICES WITH BROAD SPECTRUM ANTIMICROBIAL ACTIVITY RAAD ISSAM 2008-07-31 US disclosed
US-20070154621-A1 METHODS FOR COATING SURFACES WITH ANTIMICROBIAL AGENTS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2007-07-05 US disclosed
US-20050197634-A1 Methods for coating and impregnating medical devices with antiseptic compositions BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2005-09-08 US disclosed
US-5652093-A Analogues of reporter groups as background reducers in binding assays APROGENEX, INC. (US) 1997-07-29 US disclosed
US-5501952-A Analogues of reporter groups as background reducers in hybridization assays APROGENEX, INC. (US) 1996-03-26 US disclosed
EP-0662152-A1 ENRICHING AND IDENTYFYING FETAL CELLS IN MATERNAL BLOOD FOR IN SITU HYBRIDIZATION APROGENEX, INC. (US) 1995-07-12 EP disclosed
WO-1995003431-A1 ENRICHING AND IDENTIFYING FETAL CELLS IN MATERNAL BLOOD FOR IN SITU HYBRIDIZATION APROGENEX, INC. (US) 1995-02-02 WO disclosed
WO-1995002699-A1 ANALOGUES OF REPORTER GROUPS AS BACKGROUNG REDUCERS IN HYBRIDIZATION ASSAYS APROGENEX, INC. (US) 1995-01-26 WO disclosed
WO-1994002646-A1 ENRICHING AND IDENTYFYING FETAL CELLS IN MATERNAL BLOOD FOR IN SITU HYBRIDIZATION APROGENEX INC. (US) 1994-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277742-A1 TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG RACK1, RPL30, RRBP1 AGO2 284/4885C9 4860/4885KDM4E 1039/4885
US-10589003-B2 Methods for coating surfaces with antimicrobial agents CUTA, CD63, CDC37 AGO2 3843/4885C9 167/4885KDM4E 3147/4885
US-20090275661-A1 PREPARATION OF THE FORMAURINDICARBOXYLIC ACID BASE AND ITS DERIVATIONS AND USE ATIC, ASS1, ALDH7A1 AGO2 4297/4885C9 851/4885KDM4E 2944/4885
US-20110009490-A1 PREPARATION OF THE FORMAURINDIKARBOXYL ACID BASE AND ITS DERIVATIONS AND USE ATIC, ASS1, F7 AGO2 3875/4885C9 2031/4885KDM4E 2270/4885
US-20180303977-A1 METHODS FOR COATING SURFACES WITH ANTIMICROBIAL AGENTS CUTA, CD63, CDC37 AGO2 3843/4885C9 167/4885KDM4E 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.